China Pharma Holdings, Inc.

What they do

China Pharma Holdings, Inc. is a Nevada holding company; it is not a Chinese operating company, and all operations are run by its wholly owned subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd. and Helpson's subsidiaries in the PRC. Helpson develops, manufactures and markets pharmaceutical products for human use for high-incidence and high-mortality diseases prevalent in China, in the form of dry powder injectables, liquid injectables, tablets, capsules and cephalosporin oral solutions. As of December 31, 2025 it holds manufacturing rights for 19 pharmaceutical products across three categories: basic generic drugs, first-to-market generics and modern Traditional Chinese Medicines. It also manufactured comprehensive healthcare and protective products, and operates two production facilities in Haikou, Hainan Province.

Revenue drivers

• Prescription generic pharmaceuticals (Helpson) — The core business: 19 products, mostly sold on prescription and approved by the NMPA, including the hypertension drug Candesartan tablets, which passed generic-drug-consistency-evaluation in early August 2023. These products are made across five dosage forms (dry powder injectables, liquid injectables, tablets, capsules and cephalosporin oral solutions) and account for essentially all of the company's revenue.
• Hospital and OTC pharmacy distribution channel — Helpson supplies hospitals and OTC pharmacies indirectly through provincial and municipal pharmaceutical logistics companies holding the required Drug Supply License and GSP certification, covering the primary healthcare institution market. The filings state the company relies on distributors for all revenues.
• Comprehensive healthcare and protective products — The company states it also manufactured comprehensive healthcare products and protective products, and it continues to explore the comprehensive healthcare field. The filings do not quantify revenue from this activity.
• Centralized Procurement (CP) bid participation — Consistency evaluation is a qualification criterion for China's national Centralized Procurement program, which has sharply reduced bid-winning drug prices. Helpson weighs CP market access against the cost and time of qualification and the risk of price declines, so CP participation is a potential but discretionary revenue channel rather than a current growth driver.

Recent performance

Annual revenue fell steadily from $9.6M in 2021 to $8.1M in 2022, $7.0M in 2023, $4.5M in 2024 and $4.1M in 2025. The company reported net losses in every one of those years: $-3.4M, $-4.0M, $-3.1M, $-4.7M and $-3.2M, respectively. Diluted EPS was negative each year, at $-0.74 (2021), $-3.78 (2022), $-0.91 (2023), $-2.71 (2024) and $-0.74 (2025). Operating cash flow was negative from 2021 to 2024 before turning positive at $148,261 in 2025. Recent quarterly revenue was $756,217 for the quarter ended 2025-09-30, $1.2M for 2025-12-31, $983,536 for 2026-03-31 and $948,340 for 2026-06-30.

Strategy

Helpson says it treats China's generic-drug consistency evaluation as a top priority, but describes industry-wide slow progress because of shifting policies, market trends, expected investment and expected return on investment. It takes what it calls a cautious and flexible attitude toward starting or advancing consistency evaluation projects for existing products, since consistency evaluation is a qualification standard for Centralized Procurement and CP has sharply cut bid-winning prices. The flagship Candesartan tablets passed consistency evaluation in August 2023. The company also continues to explore the field of comprehensive healthcare, citing the Healthy China 2030 outline and its projection of a RMB 16 trillion (about $2.5 trillion) health service industry by 2030.

Risks

• Centralized Procurement price pressure — Eleven rounds of national-level CP had been implemented as of June 30, 2026, covering 316 commonly used drugs across 26 therapeutic areas in the first eight batches, and these programs have significantly reduced bid-winning prices.
• Generic competition and off-patent products — Most of the company's products are off-patent branded generics that other manufacturers can also make, and the filings state the company faces substantial competition from rivals who may develop, acquire or commercialize products earlier or more successfully.
• Consistency evaluation and regulatory compliance — The 2019 Drug Administration Law replaced GMP certification with a pilot inspection mechanism, and failure of any production line to satisfy an inspection could lead to suspension of production on that line.
• Distributor dependence — The company relies on distributors for all of its revenues and depends on a limited number of distributors for the majority of sales, so losing those relationships would materially affect the business.

Outlook

Management does not provide specific financial guidance in the excerpted filings. It says it will continue to pursue consistency evaluation actively but cautiously, balancing CP market access against the required financial and time investment and the risk of sharp price declines for drugs in the CP catalog. It also says it will continue to explore the comprehensive healthcare field. The filings caution that actual results may differ materially and that the company gives no assurances about future results.